Fluorescence-guided Resection in Breast Cancer
Launched by PHOTONAMIC GMBH & CO. KG · Apr 23, 2010
Trial Information
Current as of June 21, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Written informed consent
- • Caucasian female postmenopausal patients
- • Patients with histologically confirmed primary palpable and nonpalpable breast cancer sized up to 5 cm (T1 - T2)
- Exclusion Criteria:
- • Suspicious lymphogenic metastases (cN1-3)
- • Acute or chronic hepatic diseases
- • Manifest renal diseases with renal dysfunction
- • Relevant cardiac disease
- • Preceding therapy of breast tumour under investigation
- • Patients with multiple attempts of hook-wire placement in preparation of surgery
- • Dementia or psychic condition that might interfere with the ability to understand the study and thus give a written informed consent
- • Simultaneous participation in another clinical study or participation in another clinical study in the 30 days directly preceding treatment
About Photonamic Gmbh & Co. Kg
Photonamic GmbH & Co. KG is a leading biopharmaceutical company focused on the development and commercialization of innovative therapies in the field of oncology. With a commitment to advancing cancer treatment, Photonamic specializes in photodynamic therapy and other cutting-edge technologies aimed at improving patient outcomes. The company’s robust pipeline reflects its dedication to addressing unmet medical needs through rigorous clinical trials and a collaborative approach to research and development. By leveraging advanced scientific expertise and strategic partnerships, Photonamic is poised to make significant contributions to the future of cancer care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Munich, , Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials